Zacks Investment Research
29 May 2026, 18:25 UTC · 2h ago
Source · https://www.zacks.com/stock/news/2929409/immunitybio-anktiva-explained-and-what-comes-next?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|zer_report_insights-2929409
Read source
Search tags
Story key points
3 claims · impact-rated
ImmunityBio's total revenue grew 668% from $14.7 million in 2024 to $113.3 million in 2025. — Massive year-over-year revenue growth demonstrates successful commercial scaling of the company's lead product.
+0.60First-quarter 2026 revenue reached $44.2 million, representing a 168% increase year-over-year. — Continued strong growth in 2026 suggests the commercial momentum for Anktiva is sustainable and expanding.
+0.50Anktiva has received FDA approval in the U.S., as well as approval in the UK and conditional marketing authorization from the European Commission. — Geographic expansion into European markets increases the total addressable market and potential revenue streams.
+0.40Ticker attribution
Model heads
Continue reading
6 related stories
The company showed massive revenue growth (668% in 2025) and strong commercial momentum following the FDA approval of Anktiva.
No ticker relationship head found.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
9h ago
